Metformin for Treatment Antipsychotic Induced Amenorrhea in Female Schizophrenic Patients

Metformin for Treatment Antipsychotic Induced Amenorrhea in Female Schizophrenic Patients: a Double Blind, Placebo-controlled Study

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01206153

Enrollment

Registered

2010-09-21

Start date

2008-06-30

Completion date

2010-03-31

Last updated

2010-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amenorrhea

Brief summary

Antipsychotics such as risperidone could induce amenorrhea in schizophrenic patients. The investigators conducted a randomized, placebo-controlled study to test the efficacy of metformin for antipsychotic induced amenorrhea in schizophrenia patients.

Interventions

DRUGmetformin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 40 Years

Healthy volunteers

Inclusion criteria

* schizophrenia patient * amenorrhea for more than three months after antipsychotic treatment

Exclusion criteria

* liver or renal diseases * pregnant or lactating women * cardiovascular diseases * hypertension or diabetes mellitus

Design outcomes

Primary

Measure	Time frame	Description
prolactin level	—	the outcome measure assess a efficacy.

Secondary

Measure	Time frame
fasting glucose	—

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026